No Data
No Data
Dirui Healthcare (300396): Consolidate domestic business and accelerate expansion of overseas markets
Matters: The company publishes financial reports. The company's revenue in '23 was 1,378 million yuan (+12.96%), net profit attributable to mother was 276 million yuan (+5.26%), after deducting non-net profit of 262 million yuan (+5.36%). 2
Diri Healthcare (300396): The pace of delivery has led to quarterly fluctuations and rapid overseas growth
Guide to this report: The pace of delivery has led to quarterly fluctuations in 2023Q4 and 2024Q1 performance. Domestic market installed capacity is actively promoted. It is expected that reagent volumes will increase. Localization in the international market will continue to advance, and it is expected that rapid growth will continue. Maintain an increase in holdings rating.
Tianfeng Securities released a research report on April 23 stating that it gave Dirui Healthcare (300396.SZ) a purchase rating. The main reasons for the rating include: 1) strengthening channel empowerment, which is worth looking forward to; 2) continuing
Tianfeng Securities released a research report on April 23 stating that it gave Dirui Healthcare (300396.SZ) a purchase rating. The main reasons for the rating include: 1) strengthening channel empowerment, which is worth looking forward to; 2) continuing to increase overseas, major customer strategy+localization management upgrades drive high growth in the international market; 3) changes in product structure are expected to drive increased profitability. (Mainichi Keizai Shimbun)
Dirui Medical (300396): High performance in 2024Q1, the increase in reagent volume is worth looking forward to
Incident: On April 19, 2024, Diri Healthcare disclosed the 2023 Annual Report and 2024 Quarterly Report. In 2023, the company achieved revenue of 1,378 billion yuan, +12.96% over the same period last year; achieved return
Express News | Dirui Healthcare: Net profit of 122 million yuan in the first quarter of 2024 increased 56.73% year-on-year
Diri Healthcare (300396.SZ): Currently, revenue in the EU market accounts for a small proportion of the company's total revenue
Gelonghui, April 17 | Dirui Medical (300396.SZ) said on the investor interactive platform that the company's current revenue in the EU market accounts for a small proportion of the company's total revenue. According to rough statistics, it is less than 3%. The main products are mainly based on cost-effective urine. In response to related rumors, we communicated with local regional officials and verified with dealers who have been cooperating for many years. According to actual business feedback, the company's business is all normal and has not been affected in any way. Dirui Medical has been working in the international market for more than 20 years, and the company strictly complies with local laws and regulations to promote product sales.
No Data